→ Amgen and their partners at Allergan say their pivotal study of a Rituxan knockoff came through with positive PK results for patients with rheumatoid arthritis. They’re also running a separate pivotal for non-Hodgkin’s lymphoma which will go into their regulatory filing for an approval.
→ New boards have been established for Ironwood and its biotech spinout Cyclerion. Industry vet Julie McHugh will chair the Ironwood board while Cyclerion named Marsha Fanucci — an ex-Genzyme/Millennium exec — to the head of their new board.
→ AIT Therapeutics has licensed commercial rights for its cylinder free nitric oxide generator and phasic-flow delivery system in the US and China to Circassia Pharmaceuticals. It’s a $32.5 million deal.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.Free Subscription